Company Name: |
RD International Technology Co., Limited
|
Tel: |
18024082417 |
Email: |
market@ubiochem.com |
Products Intro: |
Product Name:KW-8232 CAS:217813-15-5 Purity:5mg;10mg;50mg;100mg;250mg;500mg;1g Package:5mg;10mg;50mg;100mg;250mg;500mg;1g
|
Company Name: |
TargetMol Chemicals Inc.
|
Tel: |
15002134094 |
Email: |
marketing@targetmol.cn |
Products Intro: |
Product Name:KW-8232 CAS:217813-15-5 Purity:0 Package:100mg/RMB 17500;50mg/RMB 13800;25mg/RMB 10600
|
|
| KW-8232 Basic information |
| KW-8232 Chemical Properties |
storage temp. | Store at -20°C | solubility | DMSO : 125 mg/mL (177.24 mM; Need ultrasonic) | form | Solid | color | White to pink |
| KW-8232 Usage And Synthesis |
Biological Activity | KW-8232, an orally active anti-osteoporotic agent, and can reduces the biosynthesis of PGE2[1].
KW-8232 is an anti-osteoporotic agent. KW-8232 reduces the biosynthesis of PGE2 in mouse osteoblastic cells[1].KW-8232 possesses anti-viral activity against SARS-CoV-2 (EC50 ~1.2 μM )[2].
KW-8232 (3, 10, 30 mg/kg, p.o.) potently increases the femoral bone mineral density (BMD) of immobilized legs of rats, and affects immobilization-induced abnormal bone turnovrer. KW-8232 markedly decreases urinary calcium excreation in the neurectomized rats only at 30 mg/kg, and highly reduces urinary pyridinoline and deoxypyridionline excretion which are markers of bone resorption in neurectomized rats. KW-8232 inhibits bone loss may be attributed to the lower prostaglandins (PGs)-stimulated bone resorption via regulation of PGE2 production[1]. | References | [1]. Uchii M, et al. Effect of KW-8232, a novel anti-osteoporotic agent, on bone loss in sciatic neurectomized rats. Jpn J Pharmacol. 1998 Oct;78(2):241-3. [2]. Shiwei Wang, et al. A Transferable Deep Learning Approach to Fast Screen Potent Antiviral Drugs against SARS-CoV-2. bioRxiv. 2020. |
| KW-8232 Preparation Products And Raw materials |
|